Published in Nat Med on February 23, 2014
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med (2015) 2.41
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data (2014) 1.76
The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21
Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell (2014) 1.20
A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet (2014) 1.17
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun (2016) 1.15
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget (2014) 1.03
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res (2015) 0.99
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. J Clin Oncol (2015) 0.96
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov (2015) 0.95
Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes. PLoS Genet (2015) 0.92
Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration. Cell Stem Cell (2016) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
The mutational landscape of endometrial cancer. Curr Opin Genet Dev (2015) 0.86
Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget (2015) 0.85
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84
SWI/SNF proteins as targets in cancer therapy. J Hematol Oncol (2014) 0.84
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun (2014) 0.84
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet (2016) 0.84
Chromatin-Remodeling-Factor ARID1B Represses Wnt/β-Catenin Signaling. Am J Hum Genet (2015) 0.83
SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet (2016) 0.81
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets (2015) 0.81
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med (2016) 0.81
Potential therapeutic targets in ARID1A-mutated cancers. Expert Opin Ther Targets (2015) 0.80
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. Cell Rep (2016) 0.80
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J (2015) 0.79
ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol Rep (2015) 0.78
The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Mol Cell Proteomics (2016) 0.76
Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol (2016) 0.76
Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov (2017) 0.76
Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1. Cancer Res (2016) 0.76
SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer. Genes Dev (2016) 0.75
CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer. Breast Cancer Res (2014) 0.75
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine. BMC Genomics (2016) 0.75
ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Hum Pathol (2016) 0.75
The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood (2016) 0.75
MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation. Cell Cycle (2016) 0.75
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci (2017) 0.75
MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. PLoS One (2017) 0.75
SWI/SNF complex in cancer. Nat Genet (2017) 0.75
CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell Syst (2017) 0.75
Epigenetic determinants of metastasis. Mol Oncol (2016) 0.75
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife (2017) 0.75
Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells. Int J Mol Sci (2017) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell (2000) 6.14
Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell (1999) 4.45
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep (2000) 3.30
ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci U S A (2008) 3.15
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res (2013) 3.08
A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol (2000) 2.70
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell (2002) 2.51
Srg3, a mouse homolog of yeast SWI3, is essential for early embryogenesis and involved in brain development. Mol Cell Biol (2001) 2.26
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A (2005) 1.96
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res (2009) 1.82
ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov (2012) 1.81
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci U S A (2013) 1.60
Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol (2010) 1.39
The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. EMBO J (2005) 1.23
Variations in the composition of mammalian SWI/SNF chromatin remodelling complexes. J Cell Biochem (2009) 1.06